A significant proportion of hospitalized patients with influenza develop complications of acute respiratory distress syndrome, driven by virus-induced cytopathic effects as well as exaggerated host immune...

A Phase III clinical trial at Emory University and 42 other U.S. sites has determined that a vitamin and steroid combination given to critically ill patients with sepsis did not improve recovery, organ...

Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said...

PRINCETON, N.J.–(BUSINESS WIRE) January 22, 2021– Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every...

McMaster University researchers have established in lab settings that a novel combination of two forms of immunotherapy can be highly effective for treating lung cancer, which causes more deaths than...

Soon after rapamycin, the first mTOR inhibitor, emerged in 1990s as a potential treatment against unwanted cell proliferation, many cancer experts had hoped emerging drugs targeting mTOR would become...

Combining a gene-targeted drug, a cancer-bursting virus and a drug that removes the immune system’s brake pedal can tackle thyroid cancer with newfound gusto, research has found. The triple-threat...

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) have identified a potential drug combination to treat uveal melanoma, a type of eye cancer. Lead author Amanda Truong,...

A clinical trial led by Mount Sinai researchers has showed for the first time that combining chemotherapy and immunotherapy can slow down metastatic bladder cancer. The trial also showed that immunotherapy...